Female Sexual Dysfunction diagnostic Tool Development

描述（由申请人提供）：1999年全国健康和社会生活调查表明，43%的美国妇女，无论男女，都有某种形式的生殖功能障碍。患有生殖功能障碍的女性除了基本的生育能力测试之外，很少有诊断、治疗和选择，尽管梅奥诊所（Mayo Clinic）报告称，受勃起功能障碍影响的美国男性中，女性所占的比例明显高于12%。造成这种差异的一个原因是很难定义和衡量女性的困难。与勃起功能障碍类似，女性问题可以作为一种孤立的身体缺陷存在，也可以作为糖尿病、心脏病或高血压的合并症存在，此外，它可以作为更年期和产后的正常部分出现，也可以作为滥用的结果出现，作为抑郁或焦虑的症状，或作为治疗这些疾病的各种药物的副作用。关于女性困难的定义和病情的复杂性，目前还没有全面的标准化方法来诊断病情，绘制病情进展图，并记录对治疗的反应，这反映了边缘性共识。目前的方法仍然严重依赖于患者的自我评估和报告，生殖困难的私密性进一步阻碍了可靠和可重复数据的收集。收集生理反应的几种选择：(1)功能非常有限，(2)在许多类型的常规功能中不可用，(3)必须在临床环境中使用。由于这些限制，甚至缺乏良好的规范性数据。

DESCRIPTION (provided by applicant): A 1999 National Health and Social Life Survey indicated that 43% of American women, both young and old, experience some form of reproductive dysfunction. Women suffering from reproductive dysfunction have had comparatively few diagnostic and treatment and options beyond basic fertility tests, despite that women comprise a significantly higher percentage than the 12% of American men reported by the Mayo Clinic to be affected by erectile dysfunction. A reason for this discrepancy is the difficulty of defining and measuring female difficulties. Similar to erectile dysfunction, female problems can exist as an isolated physical impairment or as a co-morbidity of diabetes, heart disease, or hypertension, in addition it can occur as a normal part of menopause and post-partum, or arise as a consequence of abuse, as a symptom of depression or anxiety, or as a side effect from the various medications treating these conditions. Reflecting the marginal consensus on a definition of female difficulties and the complexity of the condition, there is no comprehensive standardized method to diagnose the condition, chart its progression, and document response to treatment. Current methods remain heavily dependent on patient self-assessment and reporting, and the private nature of reproductive difficulties further hinders the collection of reliable and repeatable data. The few options for collecting physiological response are (1) of highly limited functionality, (2) not usable during many types of regular functioning, and (3) must be used in a clinical setting. Because of these limitations, there is even a lack of good normative data. Corpora Systems aims to develop and test a product that will begin to address these three deficits and become a standard diagnostic tool. Clinical trials are to be conducted at UNC-Chapel Hill School of Medicine.